RetinalGenix Technologies (RTGN) Share-based Compensation (2020 - 2026)
RetinalGenix Technologies (RTGN) posted Share-based Compensation of $10000.0 for Q1 2026, down 96.44% sequentially from $281246.0 in Q4 2025, and down 95.69% YoY from $231933.0 in Q1 2025.
RetinalGenix Technologies (RTGN) Share-based Compensation (2020 - 2026) Analysis & Trends
RetinalGenix Technologies has reported Share-based Compensation for 7 years, with the latest figure at $10000.0 in Q1 2026.
- Quarterly Share-based Compensation fell 95.69% year-over-year to $10000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10000.0 (down 99.67% YoY) and the FY2025 annual result came in at $1.0 million, down 60.13% from the prior year.
- Share-based Compensation fell to $10000.0 in Q1 2026 per RTGN's latest filing, from $281246.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $2.3 million in Q4 2024 and troughed at $10000.0 in Q1 2026.
- A 5-year average of $436279.8 and a median of $250189.0 in 2025 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2024 and 2026: Share-based Compensation surged 2107.18% in 2024, then plunged 95.69% in 2026.
- Over 5 years, Share-based Compensation stood at $586370.0 in 2022, then declined by 13.98% to $504386.0 in 2023, then soared by 349.82% to $2.3 million in 2024, then tumbled by 87.6% to $281246.0 in 2025, then tumbled by 96.44% to $10000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $10000.0, $281246.0, and $277226.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.70 Bn | 194.09 Bn | 7.27 Bn | 168.00 Mn |
| 2 | Stryker | 127.31 Bn | 123.83 Bn | 4.50 Bn | 7.00 Mn |
| 3 | Medtronic | 118.93 Bn | 109.71 Bn | 6.41 Bn | 95.00 Mn |
| 4 | Boston Scientific | 73.35 Bn | 72.82 Bn | 3.85 Bn | 87.00 Mn |
| 5 | Edwards Lifesciences | 52.11 Bn | 47.86 Bn | 1.35 Bn | 42.20 Mn |
| 6 | Dexcom | 34.35 Bn | 32.40 Bn | 830.00 Mn | 39.00 Mn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 45.00 Mn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 94.15 Mn |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn | 12.80 Mn |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - | 210,016.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10,000.00 |
| Mar 31, 2026 | 10,000.00 |
| Dec 31, 2025 | 281,246.00 |
| Dec 31, 2025 | 281,246.00 |
| Sep 30, 2025 | 277,226.00 |
| Sep 30, 2025 | 277,226.00 |
| Jun 30, 2025 | 250,189.00 |
| Jun 30, 2025 | 250,189.00 |
| Mar 31, 2025 | 231,933.00 |
| Mar 31, 2025 | 231,933.00 |
| Dec 31, 2024 | 2.27 Mn |
| Dec 31, 2024 | 2.27 Mn |
| Sep 30, 2024 | 296,256.00 |
| Sep 30, 2024 | 296,256.00 |
| Jun 30, 2024 | 211,009.00 |
| Jun 30, 2024 | 211,009.00 |
| Mar 31, 2024 | 1.73 Mn |
| Mar 31, 2024 | 1.73 Mn |
| Dec 31, 2023 | 504,386.00 |
| Dec 31, 2023 | 504,386.00 |